In breast cancer, HER2 positivity is observed in 2.5% and 3.2% of women with BRCA1 or BRCA2 mutations, respectively, compared to 27.7% and 8.2% for triple-negative tumors [46]. This evidence concerns the gene ERBB2 and breast cancer.